1. AOC™ dissolves and is eliminated from the body unchanged without any metabolic processes in 24 - 48 hours.
2. AOC™ is non-inflammatory unlike resorbable polymers that must be broken down by metabolic or inflammatory processes.
3. AOC™ does not swell as it dissolves.  It does not compress surrounding structures or disperse particulate material that may be included within the implant.
4. AOC™ is malleable and can be formulated to have a variety of handling characteristics that vary in consistency from a soft grease to a hard wax. This makes the polymer ideally suited for a wide range of medical applications.
5. AOC™ can be formulated not to contain water, so that it can serve as a carrier for compounds, such as proteins, that are not stable in an aqueous solution.

Currently FDA Approved Applications for AOC™ Polymer

1) AOC™ as a bone hemostasis material is indicated for use as a water-soluble implant material and for use in the control of bleeding from cut bone surfaces.
Approved claims include:

·       Does not interfere with bone healing

·       Does not increase infection rates

·       Non-inflammatory

2) AOC^™ as an implantable material (FDA Class II) indicated for use as a water-soluble material as an adjunct during the natural healing process.
Approved claims include:

·       Non-swelling

·       Lubricious

·       Biodissolvable

3) AOC^™ approved as a coating for porous polyethylene maxillofacial implants in the craniomaxillofacial skeleton.
Approved claims include:

·       Reduces tissue grab

·       Makes implants easier to insert into tissue pockets

·       Minimizes the debris accumulation within the pores

^·          Allows for fibrovascular tissue ingrowth

4) AOC^™ as synthetic ceramic bone grafts suspended in a matrix used in spine surgery (licensed technology).

A microscopic image of polymer crystals.